Anteris Technologies Ltd
ASX:AVR

Watchlist Manager
Anteris Technologies Ltd Logo
Anteris Technologies Ltd
ASX:AVR
Watchlist
Price: 9.3 AUD -3.93% Market Closed
Market Cap: 196.6m AUD
Have any thoughts about
Anteris Technologies Ltd?
Write Note

Anteris Technologies Ltd
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Anteris Technologies Ltd
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Anteris Technologies Ltd
ASX:AVR
Net Change in Cash
AU$17m
CAGR 3-Years
N/A
CAGR 5-Years
35%
CAGR 10-Years
N/A
Nanosonics Ltd
ASX:NAN
Net Change in Cash
AU$17.4m
CAGR 3-Years
60%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Polynovo Ltd
ASX:PNV
Net Change in Cash
-AU$940k
CAGR 3-Years
38%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SDI Ltd
ASX:SDI
Net Change in Cash
AU$253k
CAGR 3-Years
-61%
CAGR 5-Years
N/A
CAGR 10-Years
-2%
Ansell Ltd
ASX:ANN
Net Change in Cash
$752.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
48%
Next Science Ltd
ASX:NXS
Net Change in Cash
$4.2m
CAGR 3-Years
N/A
CAGR 5-Years
-2%
CAGR 10-Years
N/A
No Stocks Found

Anteris Technologies Ltd
Glance View

Market Cap
178.8m AUD
Industry
Health Care

Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm is engaged in delivering solutions that help healthcare professionals. The firm operates through two segments: operations and projects. Operation segment provides Bio implant ADAPT operations inclusive of manufacturing and sales. Project segment includes Transcatheter Aortic Valve Replacement (TAVR), which is developed using ADAPT 3D single-piece technology and other development projects across the Company. The company offers two products, ADAPT and DurAVR. ADAPT technology is a BioScaffold, which is a tissue technology platform that demonstrates zero calcification. xenograft tissue into a pure collagen scaffold with optimized strength and pliability, biocompatibility and unparalleled durability. DurAVR heart valve Is focused on delivering a functional cure in the treatment of Severe Aortic Stenosis.

AVR Intrinsic Value
0.76 AUD
Overvaluation 92%
Intrinsic Value
Price

See Also

What is Anteris Technologies Ltd's Net Change in Cash?
Net Change in Cash
17m AUD

Based on the financial report for Dec 31, 2023, Anteris Technologies Ltd's Net Change in Cash amounts to 17m AUD.

What is Anteris Technologies Ltd's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
35%

Back to Top